Sickle cell nephropathy at end-stage renal disease in the United States: patient characteristics and survival

Abbott, Kevin C.; Hypolite, Iman O.; Agodoa, Lawrence Y.

doi:10.5414/cnp58009

Cited by 128 publications

(132 citation statements)

References 0 publications

Supporting

Mentioning

118

Contrasting

Unclassified

Order By: Relevance

“…Additional characteristics are shown in Supplemental Table 1. 13 As in our study, patients with multiple myeloma were disproportionately older, male, and white, and proportions of comorbid conditions were more similar to proportions in the general population than to the recognized burden in prevalent ESRD patients. 14 The mortality rate in that study was much higher in patients with than without multiple myeloma; however, temporal trends, incidence ratios, and mortality on RRT were not reported.…”

supporting

confidence: 67%

ESRD due to Multiple Myeloma in the United States, 2001–2010

Reule

Sexton

Solid

et al. 2015

JASN

View full text Add to dashboard Cite

Although management of multiple myeloma has changed substantially in the last decade, it is unknown whether the burden of ESRD due to multiple myeloma has changed, or whether survival of patients with multiple myeloma on RRT has improved. Regarding ESRD due to multiple myeloma necessitating RRT in the United States, we evaluated temporal trends between 2001 and 2010 for demography-adjusted incidence ratios, relative to rates in [2001][2002], and mortality hazards from RRT initiation, relative to hazards in [2001][2002]. In this retrospective cohort study, we used the US Renal Data System database (n=1,069,343), 2001-2010, to identify patients with ESRD due to multiple myeloma treated with RRT (n=12,703). Demography-adjusted incidence ratios of ESRD from multiple myeloma decreased between 2001-2002 and 2009-2010 in the overall population (demography-adjusted incidence ratio 0.82; 95% confidence interval, 0.79 to 0.86) and in most demographic subgroups examined. Mortality rates were 86.7, 41.4, and 34.4 per 100 person-years in the first 3 years of RRT, respectively, compared with 32.3, 20.6, and 21.3 in matched controls without multiple myeloma. Unadjusted mortality hazards ratios declined monotonically after 2004 to a value of 0.72; 95% confidence interval, 0.67 to 0.77 in 2009-2010, and declines between 2001-2002 and 2008-2009 were observed (P,0.05) in most demographic subgroups examined. Findings were similar when adjustment was made for demographic characteristics, comorbidity markers, and laboratory test values. These data suggest the incidence of RRT from multiple myeloma in the United States has decreased in the last decade, and clinically meaningful increases in survival have occurred for these patients.

show abstract

supporting

confidence: 67%

ESRD due to Multiple Myeloma in the United States, 2001–2010

Reule

Sexton

Solid

et al. 2015

JASN

View full text Add to dashboard Cite

show abstract

“…The prevalence of end-stage renal disease (ESRD) in the adult SCD population has been estimated to be between 4 and 12%, with a mean time to ESRD of 37 years [12,13]. However, SCD represents only approximately 0.1% of all incident patients with ESRD in the USA [14].…”

Section: Sickle Cell Nephropathymentioning

confidence: 99%

Acute kidney injury in children with sickle cell disease—compounding a chronic problem

2017

View full text Add to dashboard Cite

In an article recently published in Pediatric Nephrology, Baddam and colleagues discuss the relatively underreported clinical problem of repeated episodes of acute kidney injury (AKI) in children with sickle cell disease (SCD). Their report is a cautionary note about the importance of repeated kidney injury on the background of underlying chronic kidney injury and its potential implications on long-term kidney outcome. In children and adults with SCD, this includes the effects of repeated vaso-occlusive crises and the management of these painful episodes with non-steroidal anti-inflammatory drugs. Here we review the scope of kidney involvement in SCD in children and discuss the potential short-and long-term consequences of AKI in children with SCD.

show abstract

“…On the basis of data from the US Renal Data System, patients with myeloma have an adjusted relative risk (RR) for death that is 2.5 times that of other dialysis patients and a significantly greater 2-yr mortality rate (58 versus 31%) (63). The more advanced the myeloma, the poorer the survival on dialysis.…”

Section: Cast Nephropathymentioning

confidence: 99%